Recently，the second round of project evaluation meeting of the Joint R&D Center for Innovative Drugs and High-end Formulations of China Pharmaceutical University-Zhejiang Huahai Pharmaceutical Co.(hereinafter as Zhejiang Huahai). was held in Jiangning District, Nanjing. The meeting was hosted by Dr. Xiaodi Guo, Chief Scientist of Zhejiang Huahai. Lai Maode, Academician, President of CPU, Professor Li Zhiyu, Dean of School of Pharmacy, Professor Yang Yong, Dean of School of Basic Medicine and Clinical Pharmacy, Professor Qian Hai, Dean of School of Science, and Professor Yin Lifang, Vice Dean of School of Pharmacy attended the meeting. Other participants are Professor He Chaoyong from School of Pharmacy, Professor Zhou Wei of School of Pharmacy, Dr. Li Min, Vice President of Huahai Pharmaceutical, Dr. Gu Hong, General Manager of Shanghai Syncores Pharmaceutical Co. Ltd., Dr. Deng Chengjun, Chief Medical Officer, Dr. Qiu Hongchun, Senior Vice President of Prinbery Biopharmaceutical R&D Co. Dr. Zhao Zhouming and Dr. Liu Zhi, Vice Presidents of Formulation Research Institute of Huahai Pharmaceutical, and Dr. Huang Wenzhe, Vice President of Nanjing Research Institute of Zhejiang Huahai.
President Lai Maode of China Pharmaceutical University delivered a speech on behalf of the university, highlighting that China Pharmaceutical University and Huahai Pharmaceutical have been old friends for many years, and have in-depth and extensive cooperation in various aspects such as talent training and scientific research. He mentioned that a great number of excellent students join Huahai Pharmaceutical every year, forming a virtuous school-enterprise cooperation model. Based on which, CPU hopes to further the cooperation between Zhejiang Huahai, and promote the technology transfer from universities to enterprises for win-win outcome. The university also hopes to take the opportunity of the second round of project evaluation meeting to broaden the cooperation to the level of different schools.
In total, 9 projects were evaluated at this meeting. Project leaders first reported the project background and progress. Then, the expert panels discussed the technical advantages, market value, clinical value and other aspects of the projects based on feasibility. Their constructive and prospective suggestions for each project provided valuable reference for the researchers.
It is reported that in November last year, CPU and Zhejiang Huahai jointly set up a research and development center for innovative drugs and high-end formulations in order to establish a comprehensive, long-term and stable cooperation. This joint center aims to build a platform which mutually benefits the long-term cooperation, encourages academic exchanges between the two sides, accelerates technology transfer, and enhances the enterprise's independent innovation capacity and R&D talent pool. In June this year, the Joint R&D Center for Innovative Drugs and High-end Formulations has completed the first round of project evaluation meetings, screened, and supported 5 projects. All project leaders have signed the R&D contracts successively.
Finally, both parties agreed that they would give full play to their respective advantages, carry out deep and comprehensive cooperation, take the opportunity of jointly building R&D centers to promote the transformation of relevant technology, promote the healthy development of the pharmaceutical industry and achieve a new milestone of win-win outcome.